Lucid Diagnostics (LUCD) AI Stock Analysis

• Market Cap: $139.97M
• Dividend Yield: N/A
• Average Volume (3M): 1.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.05
• Revenue Growth: 14.74%
• EPS Growth: 14.63%
• Country: US
• Employees: 72
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 137,227,500
• 10 Day Avg. Volume: 862,297
• 30 Day Avg. Volume: 1,397,377
• PEG Ratio: 0.05
• Price to Book (P/B): 7.67
• Price to Sales (P/S): 9.52
• P/FCF Ratio: -0.92
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 37.77
• Enterprise Value/Gross Profit: -58.71
• Enterprise Value/Ebitda: -3.03
• 1Y Price Target: $2.90
• Price Target Upside: 184.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-1.96% Downside)

Lucid Diagnostics' overall stock score is primarily impacted by its financial performance, which is challenged by high leverage and negative cash flows despite strong revenue growth. The technical analysis suggests a bearish trend, and the valuation is unattractive due to a negative P/E ratio. The earnings call provides some optimism with strategic partnerships and potential Medicare coverage, but operational challenges remain significant.

Positive Factors

Revenue Growth

Lucid Diagnostics' strong revenue growth indicates increasing adoption of its EsoGuard test, suggesting a growing market presence and potential for sustained expansion.

Strategic Partnerships

The partnership with Hoag Health System enhances distribution and credibility, potentially increasing EsoGuard's market penetration and long-term revenue streams.

Medicare Coverage Progress

Progress towards Medicare coverage could significantly boost EsoGuard's accessibility and reimbursement, driving long-term revenue growth and market expansion.

Negative Factors

High Leverage

High leverage increases financial risk, potentially impacting Lucid Diagnostics' ability to invest in growth opportunities and manage economic downturns.

Negative Cash Flow

Negative cash flows highlight liquidity challenges, limiting Lucid Diagnostics' ability to sustain operations and invest in future growth without external financing.

Operational Cost Challenges

High operational costs can strain financial resources, necessitating improved cost management for Lucid Diagnostics to achieve profitability and financial sustainability.

Lucid Diagnostics Business Overview & Revenue Model

Company Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

How the Company Makes Money

Lucid Diagnostics generates revenue primarily through the sale and distribution of its EsoGuard Esophageal DNA Test. The company earns money by partnering with healthcare providers, including hospitals, clinics, and gastroenterologists, who administer the test to patients. These partnerships are crucial as they extend the reach of EsoGuard to patients who are at risk of esophageal cancer or precancerous conditions. Revenue is primarily driven by the volume of tests conducted and processed, as well as through reimbursement agreements with insurance companies and healthcare payers. Additionally, Lucid Diagnostics may engage in research collaborations and licensing agreements to further expand its diagnostic offerings and market presence.

Lucid Diagnostics Financial Statement Overview

Summary

Lucid Diagnostics is experiencing rapid revenue growth, but this is overshadowed by significant profitability and cash flow challenges. The company is highly leveraged, which increases financial risk, especially given its negative margins and cash flows. While the revenue growth is promising, the company must focus on improving operational efficiency and managing its debt to achieve sustainable financial health.

Income Statement

Lucid Diagnostics has shown significant revenue growth in the TTM period, but the company is struggling with negative margins across the board. The gross profit margin, net profit margin, EBIT margin, and EBITDA margin are all negative, indicating that the company is not currently profitable. The high revenue growth rate is a positive sign, but the substantial losses suggest that the company needs to improve its cost management and operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating significant leverage, which poses a risk if the company cannot generate sufficient cash flow to service its debt. The return on equity is negative, reflecting the company's inability to generate profit from shareholders' equity. However, the equity ratio is relatively stable, suggesting that the company has a reasonable proportion of equity in its asset base.

Cash Flow

The cash flow statement shows negative operating and free cash flows, which are concerning as they indicate the company is not generating enough cash from its operations. The free cash flow to net income ratio is slightly above 1, suggesting that the company is managing its cash flow relative to its net losses. However, the overall negative cash flow growth and coverage ratios highlight liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.36M	4.35M	2.43M	377.00K	500.00K	0.00
Gross Profit	-2.81M	-3.92M	-6.05M	-3.24M	-85.00K	0.00
EBITDA	-54.36M	-44.34M	-49.75M	-54.23M	-27.41M	482.00
Net Income	-55.26M	-45.53M	-52.67M	-56.17M	-28.08M	-8.28M
Balance Sheet
Total Assets	38.67M	30.71M	27.27M	32.51M	59.00M	2.19M
Cash, Cash Equivalents and Short-Term Investments	31.12M	22.36M	18.90M	22.47M	53.66M	111.25K
Total Debt	27.55M	21.25M	15.26M	2.00M	0.00	0.00
Total Liabilities	30.81M	25.32M	29.58M	9.46M	4.26M	15.71M
Stockholders Equity	7.86M	5.39M	-2.31M	23.05M	54.74M	-13.52M
Cash Flow
Free Cash Flow	-23.03B	-44.79M	-33.04M	-30.59M	-18.53M	-5.63M
Operating Cash Flow	-23.03B	-44.14M	-32.82M	-29.68M	-17.67M	-5.63M
Investing Cash Flow	-118.61M	-646.00K	-221.00K	-4.11M	-862.00K	0.00
Financing Cash Flow	16.49B	48.25M	29.46M	2.61M	72.08M	5.58M

Lucid Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUCD, the sentiment is Negative. The current price of 1.02 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.08, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 13.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LUCD.

Lucid Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XTNT	52 Neutral	$84.24M	-18.18	-9.44%	―	15.16%	-39.18%
OWLT	48 Neutral	$142.92M	-2.51	107.86%	―	36.81%	-74.26%
LUNG	46 Neutral	$67.64M	-1.18	-82.41%	―	18.24%	4.81%
LUCD	44 Neutral	$139.97M	―	-463.56%	―	14.74%	14.63%
RCEL	42 Neutral	$145.61M	-2.78	―	―	38.32%	-1.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Lucid Diagnostics Corporate Events

Lucid Diagnostics Completes Public Offering for $26.9 Million

On September 11, 2025, Lucid Diagnostics Inc. announced the closing of its underwritten public offering of 28,750,000 shares of common stock at $1.00 per share, generating approximately $26.9 million in net proceeds. The funds are intended for working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners, and Maxim Group LLC as co-manager. This offering, made under an existing shelf registration, aims to strengthen Lucid’s financial position and support its ongoing operations in the cancer prevention diagnostics market.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Announces Public Stock Offering

On September 10, 2025, Lucid Diagnostics entered into an underwriting agreement for a public offering of its common stock, pricing each share at $1.00. The offering, managed by Canaccord Genuity LLC and BTIG, LLC, aims to raise $25 million, with potential to increase to $28.75 million if additional shares are purchased. The proceeds will support working capital and general corporate purposes, with the sale expected to close on September 11, 2025, subject to customary conditions.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.